Procept BioRobotics Corp (NASDAQ:PRCT) is a company that specializes in developing innovative robotic solutions for medical procedures. The company is known for its advanced technology in the field of urology, particularly in prostate surgery. Procept faces competition from other medical technology companies that are also developing robotic surgical systems.
On February 27, 2026, Richard Newitter from Truist Financial set a price target of $30 for PRCT. At that time, the stock was trading at $22.69, suggesting a potential increase of about 32.22%. However, recent challenges have impacted the stock's performance. Procept reported disappointing fourth-quarter sales and reduced its 2026 guidance, which has negatively affected investor sentiment.
The stock for PRCT is currently priced at $22.69, reflecting a decrease of 3.98% or $0.94. During the trading day, the stock fluctuated between a low of $22.35 and a high of $23.52. This volatility indicates uncertainty among investors following the company's recent announcements. Over the past year, PRCT has seen a high of $66.85 and a low of $19.35, highlighting the stock's significant fluctuations.
Procept's market capitalization is approximately $1.27 billion, with a trading volume of 4,470,023 shares on the NASDAQ exchange. This level of trading activity suggests that investors are actively responding to the company's recent updates. Despite the current challenges, the price target set by Truist Financial indicates potential for future growth if the company can address its recent setbacks.
